Skip to main content
. 2010 Oct 5;2(1):69–73. doi: 10.3892/ol.2010.196

Figure 2.

Figure 2

Effects of the combination treatment of ACE-I and VK on serum VEGF, sVEGFR-1 and sVEGFR-2 levels. (A) The serum VEGF level in the control group (G1) increased after 12 months, whereas the combination treatment of ACE-I and VK (G2) markedly attenuated the VEGF level as compared to the pre-treatment level. (B) No significant differences were noted in sVEGFR-1 between the pre-treatment and post-treatment levels in the two groups. (C) On the other hand, sVEGFR-2 was markedly decreased by the combination treatment of ACE-I and VK, whereas the serum level of sVEGFR2 in the control group increased. The data represent means ± SD (n=15). *Statistically significant differences between G1 and G2 (p<0.01).